• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [15923 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2015 NIHR Horizon Scanning Centre (NIHR HSC) ivWatch Model 400 patient monitor for continuous monitoring of IV sites
2015 NIHR Horizon Scanning Centre (NIHR HSC) WavSTAT4 Optical Biopsy System® for colorectal cancer diagnosis
2015 NIHR Horizon Scanning Centre (NIHR HSC) Cerepress™ and Vittamed 205™ for non-invasive intracranial pressure measurement
2015 NIHR Horizon Scanning Centre (NIHR HSC) Seralite® for multiple myeloma and other B cell dyscrasias
2015 NIHR Horizon Scanning Centre (NIHR HSC) The Nottingham Prognostic Index Plus test for breast cancer management
2015 NIHR Horizon Scanning Centre (NIHR HSC) IRIDICA system for detection and identification of microbial pathogens in critically-ill patients
2015 NIHR Horizon Scanning Centre (NIHR HSC) OncoBEAM RAS CRC for metastatic colorectal cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) myPath Melanoma for the diagnosis of malignant melanoma
2015 NIHR Horizon Scanning Centre (NIHR HSC) P1vital® eHealth Emotional Test Battery (eH-ETB) for early detection of treatment effect in depression
2015 NIHR Horizon Scanning Centre (NIHR HSC) ROCA® for the diagnosis of ovarian cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) Texture analysis of Radiological images (TexRAD) for lung cancer assessment
2015 NIHR Horizon Scanning Centre (NIHR HSC) Multistatic Array processing for Radiowave Image Acquisition (MARIA) for detection of breast tumours
2015 NIHR Horizon Scanning Centre (NIHR HSC) RhythmView™ system for cardiac arrhythmias
2015 NIHR Horizon Scanning Centre (NIHR HSC) OncAlert® and SensoDX OraTech™ for the diagnosis of oral cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) ClearSight™ MRI for breast cancer lumpectomy
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenoses]
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review]
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Balloon Eustachian tuboplasty for the treatment of Eustachian tube dysfunction - German short version and update of the correspondent EUnetHTA assessment]
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation (MitraClip®, Carillon®, NeoChord DS1000). German short version of the correspondent EUnetHTA assessment]
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) for the treatment of advanced melanoma
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Robot-assisted surgery: a systematic review of effectiveness and safety for elected indications and accumulating costs]
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [The effects of tangible and intangible incentives on health behaviour]
2015 New Zealand National Health Committee (NHC) Epidermal growth factor receptor gene mutation analysis testing assessment
2015 New Zealand National Health Committee (NHC) Percutaneous Left Atrial Appendage Occlusion (LAAO) for the prevention of stroke in non-valvular atrial fibrillation (AF) in the New Zealand health system
2015 New Zealand National Health Committee (NHC) Age-related macular degeneration
2015 New Zealand National Health Committee (NHC) Haematuria: presentation, diagnostic pathway and alternative diagnostic options
2015 The Regional Health Technology Assessment Centre (HTA-centrum) Endovenous interventions on varicose veins of the leg
2015 The Regional Health Technology Assessment Centre (HTA-centrum) Hypoglossal nerve stimulation (HGNS) for treatment of obstructive sleep apnea
2015 The Regional Health Technology Assessment Centre (HTA-centrum) Prophylactic insertion of a gastrostomy for nutritional support in patients with head and neck cancer
2015 The Regional Health Technology Assessment Centre (HTA-centrum) Oncological safety and patient-related outcomes of autologous fat grafting in breast reconstruction after breast cancer surgery
2015 The Regional Health Technology Assessment Centre (HTA-centrum) Drug eluting balloons and stents for symptomatic peripheral arterial disease
2015 The Regional Health Technology Assessment Centre (HTA-centrum) Transcranial Magnetic Resonance Guided Focused Ultrasound treatment of essential tremor, neuropathic pain and Parkinson's disease
2015 The Regional Health Technology Assessment Centre (HTA-centrum) Chlorhexidine wash prior to clean surgical procedures
2015 The Regional Health Technology Assessment Centre (HTA-centrum) [Non-surgical treatment of obesity and overweight]
2015 The Regional Health Technology Assessment Centre (HTA-centrum) Home mechanical ventilator treatment for chronic obstructive pulmonary disease patients with chronic hypercapnia
2015 Institute for Clinical Effectiveness and Health Policy (IECS) Corneal endothelial keratoplasty for the treatment of corneal endothelial dysfunction
2015 Institute for Clinical Effectiveness and Health Policy (IECS) Equine therapy and other Equine-related therapies in developmental disorders, autism spectrum disorders and cerebral palsy
2015 Institute for Clinical Effectiveness and Health Policy (IECS) [Hair micro transplant using follicular unit extraction technique for alopecia]
2015 Institute for Clinical Effectiveness and Health Policy (IECS) Mechanical insufflation-exsufflation assisted coughing in neuromuscular diseases
2015 Institute for Clinical Effectiveness and Health Policy (IECS) Cervical arthroplasty for degenerative intervertebral disc disease
2015 Institute for Clinical Effectiveness and Health Policy (IECS) Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis
2015 Institute for Clinical Effectiveness and Health Policy (IECS) 23g and 25g vitrectomy for eye conditions
2015 Institute for Clinical Effectiveness and Health Policy (IECS) Actigraphy in sleep disorder assessment
2015 Institute for Clinical Effectiveness and Health Policy (IECS) Gene panels in autistic spectrum disorders
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2]
2015 Institute of Health Economics (IHE) A systematic review of the measurement properties of self-report instruments that assess presenteeism
2015 Technology Assessment Unit of the McGill University Health Centre (MUHC) Single-dose intraoperative radiotherapy using Intrabeam® for early-stage breast cancer: an update
2015 Scottish Health Technologies Group (SHTG) Antimicrobial wound dressings (AWDs) for chronic wounds: Health technology assessment report 13
2015 Andalusian Health Technology Assessment Area (AETSA) Bioartificial liver. Systematic Review.
2015 Andalusian Health Technology Assessment Area (AETSA) Second generation prognostic genomic tests in early breast cancer: EndoPredict® y Prosigna™.
2015 Andalusian Health Technology Assessment Area (AETSA) Efficacy and safety of ecolizumab for the treatment of hemolytic syndrome atypical uremic
2015 Andalusian Health Technology Assessment Area (AETSA) FDG-PET/CT and SPECT for cancer staging.
2015 Andalusian Health Technology Assessment Area (AETSA) Focal therapy in localized prostate cancer: irreversible electroporation, HIFU and holmium laser
2015 Andalusian Health Technology Assessment Area (AETSA) Utility of QF_PCR in prenatal diagnosis of fetal aneuploidies
2015 Andalusian Health Technology Assessment Area (AETSA) Magnetic growth rods in early onset scoliosis with diverse etiology
2015 Andalusian Health Technology Assessment Area (AETSA) Stentoplasty effectiveness and safety for the treatment of osteoporotic vertebral fractures
2015 Andalusian Health Technology Assessment Area (AETSA) Active immunotherapy for lung cancer. Systematic review.
2015 Basque Office for Health Technology Assessment (OSTEBA) [An evaluation of the efficacy of psychosocial techniques (cognitive rehabilitation vs. psychoeducation) as an additional treatment to pharmacological treatment in bipolar disorder]
2015 Basque Office for Health Technology Assessment (OSTEBA) [Telemonitoring multi-pathological chronic patients with heart or lung disease. Evaluation of the implementation in Primary Care]
2015 Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the use of the new tools 2.0 and the social web in the diffusion and dissemination of the products of the agencies and units of Health Technology Assessment]
2015 Basque Office for Health Technology Assessment (OSTEBA) [Ophthalmic implants in glaucoma surgery. Safety and effectiveness analysis]
2015 Basque Office for Health Technology Assessment (OSTEBA) [Cost effective analysis of negative pressure wound therapy for the treatment of venous ulcers in legs]
2015 Basque Office for Health Technology Assessment (OSTEBA) [E-health systems to support cancer patients: proposal for the design of future assessment studies]
2015 Basque Office for Health Technology Assessment (OSTEBA) [Arthroscopy with joint washout in the treatment of knee arthrosis]
2015 Adelaide Health Technology Assessment (AHTA) Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2015 Adelaide Health Technology Assessment (AHTA) Cell salvage as a patient blood management strategy
2015 Adelaide Health Technology Assessment (AHTA) National Evidence-Based Guideline on Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes: Technical Report
2015 Adelaide Health Technology Assessment (AHTA) Systematic review of the human health effects of wind farms
2015 Adelaide Health Technology Assessment (AHTA) Screening for coronary artery disease using CT calcium scoring
2015 Adelaide Health Technology Assessment (AHTA) Endovascular clot retrieval with thrombolysis for ischaemic stroke
2015 Adelaide Health Technology Assessment (AHTA) Ultra-filtration for patients with decompensated heart failure
2015 Adelaide Health Technology Assessment (AHTA) Blood and stool biomarker testing for colorectal cancer screening
2015 Adelaide Health Technology Assessment (AHTA) Pressurised intraperitoneal aerosol chemotherapy
2015 Adelaide Health Technology Assessment (AHTA) High-frequency spinal cord stimulation and dorsal root ganglion stimulation for chronic pain
2015 Adelaide Health Technology Assessment (AHTA) Leadless Pacemaker
2015 Adelaide Health Technology Assessment (AHTA) Circulating tumour DNA assays
2015 Basque Office for Health Technology Assessment (OSTEBA) [Clinical Practice Guideline on Childhood Asthma]
2015 Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for vascular access care]
2015 Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for fall prevention]
2015 Basque Office for Health Technology Assessment (OSTEBA) [Guide to evidence-based recommendations in the prevention and treatment of pressure ulcers in adults]
2015 Norwegian Institute of Public Health (NIPH) [Autologous hematopoietic stemcell transplantation (HSCT) for multiple sclerosis]
2015 Norwegian Institute of Public Health (NIPH) A health technology assessment of the new drugs for inoperable or metastatic malignant melanoma patients
2015 Norwegian Institute of Public Health (NIPH) [Alternatives of plasma for transfusion to patients]
2015 Norwegian Institute of Public Health (NIPH) Cost-effectiveness of HPV-vaccination of boys aged 12 in a Norwegian setting
2015 Gesundheit Osterreich GmbH (GOeG) [Pharmaceutical stroke prevention in atrial fibrillation]
2015 Gesundheit Osterreich GmbH (GOeG) [Non-drug prevention and treatment of Alzheimer's dementia and mixed dementia]
2015 Canadian Agency for Drugs and Technologies in Health (CADTH) Public health interventions to reduce the secondary spread of measles
2015 Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of acamprosate calcium for alcoholism: a review of the clinical effectiveness, safety, and guidelines
2015 Andalusian Health Technology Assessment Area (AETSA) [Balloon eustachian tuboplasty for the treatment of eustachian tube dysfunction]
2015 Andalusian Health Technology Assessment Area (AETSA) [Selection criteria for direct antiviral agents for patients with chronic hepatitis c in the SSPA]
2015 Andalusian Health Technology Assessment Area (AETSA) [Simeprevir in the treatment of chronic hepatitis C. Comparative efficacy and safety assessment]
2015 Health Information and Quality Authority (HIQA) Health technology assessment of chronic disease self-management support interventions
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-22 (Umeclidinium/vilanterol)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (Addendum to Commission A14-25)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-26 (empagliflozin)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]